Pressmeddelande

BioStock: Biosergen’s CEO: “The first patient regained his health”

Cision Publicerad: 06 Sep 12:35

In Biosergen’s Q2 report, the company highlights the successful start of the phase Ib study with BSG005. The first patient with invasive fungal disease recovered and preserved both his lungs by avoiding surgery after being treated with BSG005, something the company describes as “very remarkable.” BioStock reached out to CEO Tine Olesen to learn more about this success and the company’s financial status.

Read the interview with Tine Olesen at biostock.se:

https://www.biostock.se/en/2024/09/biosergens-ceo-the-first-patient-regained-his-health/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Biosergen

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!